Claims for Patent: 8,753,679

Summary for Patent: 8,753,679

Title:	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Abstract:	A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
Inventor(s):	Radhakrishnan; Ramachandran (Fremont, CA), Vladyka; Ronald (Somerset, NJ), Sultzbaugh; Kenneth (Bridge Water, NJ)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	13/776,079
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,753,679
Patent Claims:	1. A capsule comprising a pharmaceutical formulation of 5-methyl-1-phenyl-2-(1H)-pyridone, wherein said pharmaceutical formulation comprises pharmaceutically acceptable excipients and 5-methyl-1-phenyl-2-(1H)-pyridone, and the formulation is stable for at least 9 months at 40.degree. C. at 75% relative humidity, as measured by a dissolution of at least 85% of the 5-methyl-1-phenyl-2-(1H)-pyridone after the at least 9 months. 2. The capsule of claim 1, wherein said excipients comprise one or more selected from the group consisting of disintegrators, binders, fillers, and lubricants. 3. The capsule of claim 2, wherein said disintegrators comprise one or more selected from the group consisting of agar-agar, algins, calcium carbonate, carboxmethylcellulose, cellulose, clays, colloid silicon dioxide, croscarmellose sodium, crospovidone, gums, magnesium aluminium silicate, methylcellulose, polacrilin potassium, sodium alginate, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone hydroxypropylcellulose, sodium starch glycolate, and starch. 4. The capsule of claim 2, wherein said binders comprise one or more selected from the group consisting of microcrystalline cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, and polyvinylpyrrolidone. 5. The capsule of claim 2, wherein said fillers comprise one or more selected from the group consisting of calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, dextrates, dextrin, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, matitol, maltodextrins, maltose, sorbitol, starch, sucrose, sugar, and xylitol. 6. The capsule of claim 2, wherein said lubricants comprise one or more selected from the group consisting of agar, calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, glycols, sodium benzoate, sodium lauryl sulfate, sodium stearyl, sorbitol, stearic acid, talc, and zinc stearate. 7. The capsule of claim 2, wherein by weight said disintegrator is 2-10%, said binder is 2-30%, said filler is 2-30%, and said lubricant is 0.3-0.8%. 8. The capsule of claim 2, wherein said excipients further comprise povidone. 9. The capsule of claim 8, wherein by weight said povidone is 1-4%. 10. The capsule of claim 9, wherein the capsule comprises 100-400 mg 5-methyl-1-phenyl-2-(1H)-pyridone. 11. A method for treating a fibrotic condition or inhibiting actions of cytokines, comprising administering the capsule of claim 1 to a patient suffering from said fibrotic condition or suffering from a disorder mediated by said cytokines. 12. The method of claim 11, wherein said fibrotic condition is one selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, keloid, dermal fibrosis, coronary restenosis, and post-surgical adhesions. 13. The method of claim 12, wherein said pulmonary fibrosis is one selected from the group consisting of idiopathic pulmonary fibrosis and Hermansky-Pudlak Syndrome. 14. A method of claim 11, wherein said fibrotic condition is scleroderma with pulmonary fibrosis. 15. The method of claim 11, wherein said cytokines comprise one or more selected from the group consisting of TNF-.alpha., TGF-.beta.1, bFGF, PDGF, and EGF. 16. The method of claim 15, wherein said disorder is one selected from the group consisting of multiple sclerosis, arthritis, asthma, chronic rhinitis, and edema. 17. The method of claim 11, further comprising administering one or more said capsules to said patient one or more times a day, wherein the total intake of 5-methyl-1-phenyl-2-(1H)-pyridone is at least 1200 mg a day. 18. The method of claim 17, wherein said one or more capsules are administered to the patient twice a day. 19. The method of claim 18, wherein said one or more capsules are administered to the patient three times a day. 20. The capsule of claim 8, wherein said povidone comprises at least about 1.85% by weight of the formulation. 21. The capsule of claim 8, wherein said povidone comprises at least about 1% by weight of the formulation. 22. The capsule of claim 2, wherein the formulation comprises a wet-granulated mixture comprising 5-methyl-1-phenyl-2-(1H)-pyridone, binder, filler, and disintegrator. 23. The capsule of claim 2, wherein: the pharmaceutically acceptable excipients comprise a lubricant, a filler, and a disintegrator; the binder comprises microcrystalline cellulose and povidone; the povidone is included in an amount of 1-4% by weight of the formulation; the total amount of binder is 2-30% by weight of the formulation; and the formulation comprises a wet-granulated mixture comprising the 5-methyl-1-phenyl-2-(1H)-pyridone , the binder, the filler, and the disintegrator. 24. The capsule of claim 1, wherein said pharmaceutical formulation comprises, by weight, 5-30% of the pharmaceutically acceptable excipients and 70-95% of the 5-methyl-1-phenyl-2- (1H)-pyridone. 25. The method of claim 11, wherein the fibrotic condition is a pulmonary fibrotic condition. 26. A capsule comprising a pharmaceutical formulation of 5 methyl-1-phenyl-2-(1H)-pyridone, wherein said pharmaceutical formulation comprises pharmaceutically acceptable excipients and 5-methyl-1-phenyl-2-(1H)-pyridone, and the formulation is stable for at least 18 months at 25.degree. C. at 60% relative humidity, as measured by a dissolution of at least 93% of the 5-methyl-1-phenyl-2-(1H)-pyridone after the at least 18 months.